ArticleJournal of neuroinflammation2023
Chronic kidney disease promotes cerebral microhemorrhage formation.
Article in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- From Dysbiosis to Blood-Brain Barrier Disruption: The Metabolite-Mediated Gut-Brain Axis in Alzheimer's Disease.Molecular neurobiology · 2026Review
- The Kidney-Brain Axis in Chronic Kidney Disease: Uremic Toxins, Cognitive Decline, Mechanistic Pathways, Biomarkers and Therapeutic Perspectives.Biomedicines · 2026Review
- Investigating the Kidney-Gut-Brain Axis in CKD: Uremic Toxins and Brain Microhemorrhages.International journal of molecular sciences · 2026Article
- The Role of Diet and Gut Microbiome in CKD Progression and Therapy.Journal of clinical medicine · 2026Review
- Chronic Kidney Disease Severity and Risk of Cognitive Impairment.JAMA network open · 2026Article
- Chronic Kidney disease and cognitive frailty in aging: molecular crosstalk and clinical implications.Frontiers in aging neuroscience · 2026Review
- Gut dysbiosis and brain microhemorrhages in young vs. aged mice with chronic kidney disease.Scientific reports · 2025Article
- Uremic Toxins, CKD, and Cognitive Dysfunction.Journal of the American Society of Nephrology : JASN · 2025Review
- Associations of Cerebral Small Vessel Disease and Chronic Kidney Disease in Patients With Acute Ischemic Stroke.Journal of the American Heart Association · 2025Article
- Development of cerebral microhemorrhages in a mouse model of hypertension.Journal of neuroinflammation · 2025Article
- Albumin/fibrinogen ratio (AFR): a significant predictor of postoperative delirium in older patients undergoing non-neurosurgical and non-cardiac surgery.BMC geriatrics · 2025Article
- Chronic kidney disease as a catalyst for cerebral microbleeds: understanding the underlying mechanisms and treatment approaches.Frontiers in medicine · 2025Review
- Research progress on the kidney-gut-brain axis in brain dysfunction in maintenance hemodialysis patients.Frontiers in medicine · 2025Review
- The microbial metabolite trimethylamine N-oxide and the kidney diseases.Frontiers in cellular and infection microbiology · 2025Review
- Adenine-induced animal model of chronic kidney disease: current applications and future perspectives.Renal failure · 2024Review
- Article
- circRNA-PTPN4 mediated regulation of FOXO3 and ZO-1 expression: implications for blood-brain barrier integrity and cognitive function in uremic encephalopathy.Cell biology and toxicology · 2024Article
- Clonal haematopoiesis, ageing and kidney disease.Nature reviews. Nephrology · 2024Review
- Logistic regression model for predicting risk factors and contribution of cerebral microbleeds using renal function indicators.Frontiers in neurology · 2024Article
- Erythrocyte-brain endothelial interactions induce microglial responses and cerebral microhemorrhages in vivo.Journal of neuroinflammation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundChronic kidney disease (CKD) is increasingly recognized as a stroke risk factor, but its exact relationship with cerebrovascular disease is not well-understood. We investigated the development of cerebral small vessel disease using in vivo and in vitro models of CKD.
methodsCKD was produced in aged C57BL/6J mice using an adenine-induced tubulointerstitial nephritis model. We analyzed brain histology using Prussian blue staining to examine formation of cerebral microhemorrhage (CMH), the hemorrhagic component of small vessel disease and the neuropathological substrate of MRI-demonstrable cerebral microbleeds. In cell culture studies, we examined effects of serum from healthy or CKD patients and gut-derived uremic toxins on brain microvascular endothelial barrier.
resultsCKD was induced in aged C57BL/6J mice with significant increases in both serum creatinine and cystatin C levels (p < 0.0001) without elevation of systolic or diastolic blood pressure. CMH was significantly increased and positively correlated with serum creatinine level (Spearman r = 0.37, p < 0.01). Moreover, CKD significantly increased Iba-1-positive immunoreactivity by 51% (p < 0.001), induced a phenotypic switch from resting to activated microglia, and enhanced fibrinogen extravasation across the blood-brain barrier (BBB) by 34% (p < 0.05). On analysis stratified by sex, the increase in CMH number was more pronounced in male mice and this correlated with greater creatinine elevation in male compared with female mice. Microglial depletion with PLX3397 diet significantly decreased CMH formation in CKD mice without affecting serum creatinine levels. Incubation of CKD serum significantly reduced transendothelial electrical resistance (TEER) (p < 0.01) and increased sodium fluorescein permeability (p < 0.05) across the endothelial monolayer. Uremic toxins (i.e., indoxyl sulfate, p-cresyl sulfate, and trimethylamine-N-oxide) in combination with urea and lipopolysaccharide induced a marked drop in TEER compared with the control group (p < 0.0001).
conclusionsCKD promotes the development of CMH in aged mice independent of blood pressure but directly proportional to the degree of renal impairment. These effects of CKD are likely mediated in part by microglia and are associated with BBB impairment. The latter is likely related to gut-derived bacteria-dependent toxins classically associated with CKD. Overall, these findings demonstrate an important role of CKD in the development of cerebral small vessel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.